Showing results (11-20 of 154) with videos related to
Sort By:
Pageof 16
Cancer Control : Journal of the Moffitt Cancer Center|December 7, 2011
Front-line therapy for chronic lymphocytic leukemiaSheetal Desai, Javier Pinilla-IbarzJournal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
New agents in the treatment of chronic myelogenous leukemiaJavier Pinilla-Ibarz, Alfonso Quintas-CardamaCancer Control : Journal of the Moffitt Cancer Center|January 11, 2013
Developing strategies in the immunotherapy of leukemiasJason B Brayer, Javier Pinilla-IbarzBlood|March 28, 2015
Life after ibrutinib? A new unmet need in CLLJavier Pinilla-Ibarz, Julio C ChavezBiologics : Targets & Therapy|March 26, 2016
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibJosephine Emole, Taiwo Talabi, Javier Pinilla-IbarzPatient Preference and Adherence|July 22, 2014
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsKendra Sweet, Javier Pinilla-Ibarz, Ling ZhangP & T : a Peer-Reviewed Journal for Formulary Management|August 2, 2014
Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemiaSapna Parmar, Khilna Patel, Javier Pinilla-IbarzJournal of Hematology & Oncology|July 23, 2013
Biomarkers for determining the prognosis in chronic myelogenous leukemiaKendra Sweet, Ling Zhang, Javier Pinilla-IbarzBlood Advances|December 27, 2022
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?Wael Gamal, Eva Sahakian, Javier Pinilla-IbarzExpert Review of Clinical Immunology|May 21, 2011
Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemiaCeleste Bello, Marays Veliz, Javier Pinilla-IbarzPageof 16